Saturn TMVR System

For clinically significant mitral regurgitation (MR) patients, TMVR design matters.
The Saturn TMVR system is a novel, investigational device designed to overcome clinical hurdles
to enable treatment of a wider patient range.

Saturn TMVR System consists of a bovine and porcine pericardial valve and an annular structure, implanted as a single device that embraces the native leaflets and reduces the annulus to provide secure anchoring and a reliable seal, eliminating MR and restoring proper valve function.

Saturn TMVR Key Features and Advantages:

Mechanical connection between central valve and annular structure.
Low profile in the ventricle to reduce the risk of left ventricular outflow tract (LVOT) obstruction.
Connecting arms immobilize the native mitral valve leaflets, preventing systolic anterior motion (SAM).
Mitral annulus constrained to achieve more physiological dimensions and prevent further expansion.
Low profile in the atrium to avoid flow disturbances.
Long-term stabilization provided by annular structure, minimizing the risk of late paravalvular leakage and migration.
Two valve sizes to accommodate a wide range of annulus sizes.
29Fr Valve Delivery System.

How It Works

Saturn TMVR System offers a minimally invasive alternative for patients with symptomatic mitral regurgitation of grade 3+ or 4+.
The technology is currently being validated transseptally in the CASSINI-EU and CASSINI-US early feasibility clinical trials, after showing promising results in the transapical Pilot Study.
Check the News section to be up-to-date with our clinical progresses.

CAUTION: Investigational device. The SATURN Transcatheter Mitral Valve Replacement (TMVR) System is limited by Federal (or United States) law to investigational use and is not commercially available in any country.